{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:16:14Z","timestamp":1726470974825},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.critrevonc.2013.12.010","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T15:17:52Z","timestamp":1387293472000},"page":"181-189","source":"Crossref","is-referenced-by-count":4,"title":["Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11\u201312, 2013"],"prefix":"10.1016","volume":"90","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Bocchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Gambacorti-Passerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Gozzini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Pregno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Rege-Cambrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgina","family":"Specchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2013.12.010_bib0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia \u2013 advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.hoc.2004.03.008","article-title":"Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation","volume":"18","author":"Melo","year":"2004","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR-ABL oncogene","volume":"40","author":"Sattler","year":"2003","journal-title":"Semin Hematol"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1615\/CritRevOncog.v17.i1.30","article-title":"Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukemia","volume":"17","author":"Yeung","year":"2012","journal-title":"Crit Rev Oncog"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0035","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1182\/blood-2004-08-3097","article-title":"The development of imatinib as a therapeutic agent for chronic myeloid leukaemia","volume":"105","author":"Deininger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0040","volume":"112","author":"O\u2019Brien","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0045","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0050","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0060","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0065","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood.V120.21.1676.1676","article-title":"ENESTnd 4-year update: continued superiority of nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP)","volume":"120","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0070","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3324\/haematol.12588","article-title":"Monitoring treatment of chronic myeloid leukemia","volume":"92","author":"Baccarani","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0075","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1182\/blood-2007-09-110189","article-title":"Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods","volume":"111","author":"Kantarjian","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0080","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0085","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2009-02-163485","article-title":"How I monitor residual disease in chronic myeloid leukemia","volume":"114","author":"Radich","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0090","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/cncr.23427","article-title":"Molecular monitoring in chronic myeloid leukemia","volume":"112","author":"Jabbour","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0095","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Highes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0100","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2403077","article-title":"FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white bone marrow cells in CML patients treated with imatinib","volume":"17","author":"Reinhold","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0105","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2009-07-229864","volume":"114","author":"Testoni","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0110","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0115","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood.V120.21.2790.2790","article-title":"High BCR-ABL levels at diagnosis are associated with unfavourable responses to imatinib mesylate","volume":"120","author":"Vigneri","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0120","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-years follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0125","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.leukres.2013.04.001","article-title":"The role of comorbidities in chronic myeloid leukemia","volume":"37","author":"Breccia","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.leukres.2012.03.010","article-title":"Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf","volume":"36","author":"Breccia","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0135","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0140","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1200\/JCO.2011.39.6655","article-title":"Not only response but early response to tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"30","author":"Cortes","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0145","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0150","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0155","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0160","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.canlet.2012.03.021","article-title":"How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages","volume":"322","author":"Breccia","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0165","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increate risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"issue":"Suppl. 7","key":"10.1016\/j.critrevonc.2013.12.010_bib0170","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","article-title":"Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Baccarani","year":"2012","journal-title":"Ann Oncol"},{"year":"2013","series-title":"Chronic myeloid leukemia. Version 4.2013 NCCN.org","author":"NCCN Clinical Practice Guidelines in Oncology","key":"10.1016\/j.critrevonc.2013.12.010_bib0175"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0180","first-page":"701","article-title":"Delaying the initiation of dasatinib after imatinib failure has a negative impact on outcome for patients with CP-CML: results from a European observational study (FORTE; CA 180-211)","volume":"96","author":"Morra","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0185","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0190","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood.V120.21.167.167","volume":"120","author":"Hochhaus","year":"2012","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2013.12.010_bib0195","first-page":"192","article-title":"Molecular response kinetics and bcr-abl reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-years follow-up","volume":"97","author":"Hochhaus","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0200","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/leu.2012.104","article-title":"Standardized definitions of molecular response in chronic myeloid leukemia","volume":"26","author":"Cross","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","article-title":"Why do stem CML cells survive allogeneic stem cell transplantation or imatinib? Does it really matter","volume":"47","author":"Goldman","year":"2006","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0210","first-page":"632","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission: update results of the STIM study","volume":"114","author":"Mahon","year":"2011","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2013.12.010_bib0215","article-title":"Frequent and sustained drug-free remission in the Australasian CML8 trial of imatinib withdrawal","volume":"97","author":"Ross","year":"2012","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"10.1016\/j.critrevonc.2013.12.010_bib0220","article-title":"Loss of major molecular response is accurate for restarting imatinib after imatinib discontinuation in CP-CML patients with long lasting CMR: importance of fluctuating values of MRD and interferon","volume":"97","author":"Rousselot","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2013.12.010_bib0225","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable Bcr-Aabl transcripts: results from the French CML group (FILMC)","volume":"114","author":"Rea","year":"2011","journal-title":"Blood"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813002655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842813002655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T04:40:41Z","timestamp":1597207241000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842813002655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1040842813002655"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2013.12.010","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}